These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15790802)

  • 21. Nonsteroidal anti-inflammatory drugs for perioperative pain control.
    Burgess FW; Browning RA
    Med Health R I; 2001 Oct; 84(10):327-8. PubMed ID: 11693050
    [No Abstract]   [Full Text] [Related]  

  • 22. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee.
    Weaver A; Rubin B; Caldwell J; McMahon FG; Lee D; Makarowski W; Offenberg H; Sack M; Sikes D; Trapp R
    Clin Ther; 1995; 17(4):735-45. PubMed ID: 8565037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee.
    Zhao SZ; Dedhiya SD; Bocanegra TS; Fort JG; Kuss ME; Rush SM
    Clin Ther; 1999 Jan; 21(1):205-17. PubMed ID: 10090436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
    Hsiao FY; Tsai YW; Huang WF
    Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners.
    Kerr SJ; Mant A; Horn FE; McGeechan K; Sayer GP
    Med J Aust; 2003 Oct; 179(8):403-7. PubMed ID: 14558862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
    Schnitzer TJ; Weaver AL; Polis AB; Petruschke RA; Geba GP;
    J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tailoring arthritis therapy in the wake of the NSAID crisis.
    Olsen NJ
    N Engl J Med; 2005 Jun; 352(25):2578-80. PubMed ID: 15972863
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
    Whelton A; White WB; Bello AE; Puma JA; Fort JG;
    Am J Cardiol; 2002 Nov; 90(9):959-63. PubMed ID: 12398962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials.
    Battisti WP; Katz NP; Weaver AL; Matsumoto AK; Kivitz AJ; Polis AB; Geba GP
    J Pain; 2004 Nov; 5(9):511-20. PubMed ID: 15556830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

  • 34. Early trials probe COX-2 inhibitors' cancer-fighting potential.
    Ziegler J
    J Natl Cancer Inst; 1999 Jul; 91(14):1186-7. PubMed ID: 10413412
    [No Abstract]   [Full Text] [Related]  

  • 35. [Cyclooxygenase 2 inhibitors and lung carcinoma].
    Spano JP; Chouahnia K; Morère JF
    Bull Cancer; 2004 May; 91 Suppl 2():S109-12. PubMed ID: 15899634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
    Rahme E; Hunsche E; Toubouti Y; Chabot I
    Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs.
    Weideman RA; Kelly KC; Kelley CL; Cryer B
    Am J Manag Care; 2002 Oct; 8(10):869-77. PubMed ID: 12395955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoption of celecoxib and rofecoxib: a nationwide database study.
    Helin-Salmivaara A; Huupponen R; Virtanen A; Klaukka T
    J Clin Pharm Ther; 2005 Apr; 30(2):145-52. PubMed ID: 15811167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension.
    Osterhaus JT; Burke TA; May C; Wentworth C; Whelton A; Bristol S
    Clin Ther; 2002 Jun; 24(6):969-89. PubMed ID: 12117086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.